Home › Funds › Paradigm Biocapital Advisors LP › ORIC
Paradigm Biocapital Advisors LP position in ORIC
ORIC PHARMACEUTICALS INC · Health Care
Paradigm Biocapital Advisors LP reported holding 1,505,769 shares of ORIC (ORIC PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$20.3M, representing 0.40% of its reported portfolio and ranking #22 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed ORIC holdings in 3 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's ORIC position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in ORIC in Q4 2025 at 2,401,217 shares (US$19.6M). The position peaked in Q1 2026 at 1,701,217 shares, worth US$21.6M. Across 3 filings, Paradigm Biocapital Advisors LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,505,769 shares valued at US$20.3M. Notable position changes include a 29% trim in Q1 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.40M | $19.64M | New |
| Q1 2026 | 1.70M | $21.55M | Reduce |
| Q3 2026 | 1.51M | $20.28M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORIC and 13F data
ORIC (ORIC PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in ORIC — the largest reported positions include Nextech Invest Ltd. (US$77.6M), AIHC Capital Management Ltd (US$62.4M), SR ONE CAPITAL MANAGEMENT, LP (US$50.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORIC
- Nextech Invest Ltd. 7.16M sh · $77.57M · Q2 2026
- AIHC Capital Management Ltd 4.63M sh · $62.38M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.62M sh · $49.98M · Q2 2026
- Venrock Adviser, LLC 4.32M sh · $46.78M · Q2 2026
- Siren, L.L.C. 3.36M sh · $45.23M · Q3 2026
- NEA Management Company, LLC 4.12M sh · $44.60M · Q2 2026
- EcoR1 Capital, LLC 3.03M sh · $40.79M · Q3 2026
- Column Group LLC 3.54M sh · $38.35M · Q2 2026
- First Turn Management, LLC 1.57M sh · $21.21M · Q3 2026
- MPM BioImpact LLC 1.88M sh · $20.38M · Q2 2026
- Integral Health Asset Management, LLC 1.70M sh · $20.20M · Q3 2026
- Vivo Capital, LLC 924.39K sh · $12.45M · Q3 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held ORIC?
Paradigm Biocapital Advisors LP has disclosed ORIC holdings in 3 of the last 4 reported quarters, going back to Q4 2025.
What is Paradigm Biocapital Advisors LP's current position in ORIC?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 1.51M shares of ORIC (ORIC PHARMACEUTICALS INC), valued at $20.28M, representing 0.40% of its reported portfolio and ranking #22.
Has Paradigm Biocapital Advisors LP been buying or selling ORIC?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP newly opened its position in ORIC. The position peaked in Q1 2026 at 1.70M shares.
Which other funds hold ORIC?
Other major institutional holders of ORIC include Nextech Invest Ltd., AIHC Capital Management Ltd, SR ONE CAPITAL MANAGEMENT, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.